AUG 03, 2020 1:56 PM PDT

Improving Diagnostics in Breast Cancer

WRITTEN BY: Jasper Cantrell

Diagnostics is one of the essential tools in a physician’s toolkit. A good diagnostic test can identify whether a patient has a disease, the severity of the disease, and what treatments might work best for that patient.

Breast cancer represents a perfect example of how effective diagnostics can be. Most breast cancers fall under HER2+, ER+, or PR+ subtypes.  Each can be diagnosed using a test and come with tailored treatments. These tests are usually immunohistochemistry assays. These assays stain for a particular protein and score the patient based on how much of said protein is there have been extremely useful in recent decades. A group from Qingdao University in affiliation with Quanticision Diagnostics developed a new assay that might be even more effective.  The quantum dot blot.

Their quantum dot blot uses a special nitrocellulose plate in the test instead of the standard plate normally used. Nitrocellulose binds proteins better than the standard plates. They would also utilize fluorescence instead of standard staining, which would speed up the analysis portion of the test. Both of these combined would make a faster test that needed less of the patient’s sample.

In this study, they intended to validate the quantum dot blot by comparing it to the available immunohistochemistry tests. They developed a simple protocol similar to immunohistochemical tests and used HER2+ or HER2- patients as the test group. The quantum dot blot identified HER2+ samples just as well as immunohistochemistry testing. Using a “gold standard” method called FISH, they further validated that the QDB test could identify HER2+ samples with just as much accuracy as current testing methods.

Not to waste an opportunity, the team decided to analyze HER2+ test results, and identify any correlations. They found that grade three patients were five-fold more likely to have a HER2+ tumor than grade one. This may be due to lapses in treatment, as HER2+ therapies are relatively standard nowadays, but the team did not elaborate on their findings.

The study states, “To the best of our knowledge, this is the first time protein biomarker was measured absolutely and quantitatively in FFPE samples using an immunoassay.” Improvements to the methodology are a hallmark of science and help improve testing in labs and the hospital. The quantum dot blot test outlined in this study decreases the amount of patient sample needed and speeds up the process. The fluorescent reporter also makes quantitative, rather than qualitative results, which can reduce bias from doctors or lab technicians.

All-in-all, this study shows the quantum dot blot improves upon current immunohistochemical diagnostic tests. New tests like this often experience a slow implementation, as they sometimes need non-standard reagents and intensive validation. Still, with any luck, it can make the diagnosis of HER2+ breast cancer and other diseases more efficient.

Sources: Nature Scientific Reports, Vector Laboratories Inc
 

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
JUL 15, 2020
Cancer
Traditional Medicine Reveals a New Anti-Cancer Drug
JUL 15, 2020
Traditional Medicine Reveals a New Anti-Cancer Drug
The art of traditional eastern medicine dates back thousands of years. It uses many unproven remedies, and many consider ...
JUL 31, 2020
Cancer
Using Electric Fields to Treat Brain Cancer
JUL 31, 2020
Using Electric Fields to Treat Brain Cancer
One of the great things about research is its creativity, which can lead to interesting experiments, odd but impactful i ...
AUG 07, 2020
Cancer
Immune-Related Genes as Prognostic Biomarkers
AUG 07, 2020
Immune-Related Genes as Prognostic Biomarkers
Cancer is one of the most persistent and hardy diseases. Cancers often develop the ability to suppress the immune system ...
AUG 06, 2020
Clinical & Molecular DX
Device Diagnoses Breast Cancer in 60 Minutes
AUG 06, 2020
Device Diagnoses Breast Cancer in 60 Minutes
Researchers have created a point-of-care device that can provide diagnostic results for breast cancer in under an hour. ...
AUG 06, 2020
Clinical & Molecular DX
Gut Feeling: Spotting the Early Signs of Gastric Cancer
AUG 06, 2020
Gut Feeling: Spotting the Early Signs of Gastric Cancer
In a study published in Science Advances, scientists propose a new method for diagnosing gastric cancer, the third leadi ...
SEP 01, 2020
Cancer
Honeybee venom destroys triple-negative breast cancer cells
SEP 01, 2020
Honeybee venom destroys triple-negative breast cancer cells
New research published in the international journal npj Precision Oncology reports that honeybee venom is capa ...
Loading Comments...